Search Results

There are 14273 results for: content related to: Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study

  1. You have free access to this content
    Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

    British Journal of Haematology

    Volume 155, Issue 5, December 2011, Pages: 599–606, Lieke H. van der Helm, Canan Alhan, Pierre W. Wijermans, Marinus van Marwijk Kooy, Ron Schaafsma, Bart J. Biemond, Aart Beeker, Mels Hoogendoorn, Bastiaan P. van Rees, Okke de Weerdt, Jurgen Wegman, Ward J. Libourel, Sylvia A. Luykx-de Bakker, Monique C. Minnema, Rolf E. Brouwer, Fransien Croon-de Boer, Matthijs Eefting, Kon-Siong G. Jie, Arjan A. van de Loosdrecht, Jan Koedam, Nic J. G. M Veeger, Edo Vellenga and Gerwin Huls

    Version of Record online : 8 OCT 2011, DOI: 10.1111/j.1365-2141.2011.08893.x

  2. You have free access to this content
    Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: An analysis from a regional healthcare network

    American Journal of Hematology

    Volume 89, Issue 12, December 2014, Pages: E244–E252, Pierre Bories, Sarah Bertoli, Emilie Bérard, Julie Laurent, Eliane Duchayne, Audrey Sarry, Eric Delabesse, Odile Beyne-Rauzy, Françoise Huguet and Christian Récher

    Version of Record online : 20 OCT 2014, DOI: 10.1002/ajh.23848

  3. You have free access to this content
    Azacitidine for the treatment of patients with acute myeloid leukemia

    Cancer

    Volume 118, Issue 4, 15 February 2012, Pages: 1014–1022, Luca Maurillo, Adriano Venditti, Alessandra Spagnoli, Gianluca Gaidano, Dario Ferrero, Esther Oliva, Monia Lunghi, Alfonso M. D'Arco, Alessandro Levis, Domenico Pastore, Nicola Di Renzo, Alberto Santagostino, Vincenzo Pavone, Francesco Buccisano and Pellegrino Musto

    Version of Record online : 14 JUL 2011, DOI: 10.1002/cncr.26354

  4. You have full text access to this Open Access content
    Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes

    Cancer Science

    Volume 102, Issue 9, September 2011, Pages: 1680–1686, Toshiki Uchida, Yoshiaki Ogawa, Yukio Kobayashi, Takayuki Ishikawa, Haruhiko Ohashi, Tomoko Hata, Noriko Usui, Masafumi Taniwaki, Kazunori Ohnishi, Hideki Akiyama, Keiya Ozawa, Kazuma Ohyashiki, Shinichiro Okamoto, Akihiro Tomita, Shinji Nakao, Kensei Tobinai, Michinori Ogura, Kiyoshi Ando and Tomomitsu Hotta

    Version of Record online : 12 JUL 2011, DOI: 10.1111/j.1349-7006.2011.01993.x

  5. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia

    British Journal of Haematology

    Volume 169, Issue 2, April 2015, Pages: 199–210, Andrew Wei, Peter Tan, Sarah Perruzza, Chindu Govindaraj, Shaun Fleming, Julie McManus, Sharon Avery, Sushrut Patil, William Stevenson, Magdalena Plebanski and Andrew Spencer

    Version of Record online : 2 FEB 2015, DOI: 10.1111/bjh.13281

  6. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine

    European Journal of Haematology

    Volume 85, Issue 2, August 2010, Pages: 130–138, Valeria Santini, Pierre Fenaux, Ghulam J. Mufti, Eva Hellström-Lindberg, Lewis R. Silverman, Alan List, Steven D. Gore, John F. Seymour, Jay Backstrom and Charles L. Beach

    Version of Record online : 12 APR 2010, DOI: 10.1111/j.1600-0609.2010.01456.x

  7. You have free access to this content
    Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

    British Journal of Haematology

    Volume 161, Issue 3, May 2013, Pages: 339–347, Yun-Gyoo Lee, Inho Kim, Sung-Soo Yoon, Seonyang Park, June Won Cheong, Yoo Hong Min, Jeong-Ok Lee, Soo-Mee Bang, Hyeon Gyu Yi, Chul Soo Kim, Yong Park, Byung-Soo Kim, Yeung-Chul Mun, Chu-Myoung Seong, Jinny Park, Jae Hoon Lee, Sung-Yong Kim, Hong Ghi Lee, Yeo-Kyeoung Kim and Hyeoung-Joon Kim, for the Korean Society of Haematology AML/MDS working party

    Version of Record online : 21 FEB 2013, DOI: 10.1111/bjh.12256

  8. You have free access to this content
    Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C

    British Journal of Haematology

    Volume 149, Issue 2, April 2010, Pages: 244–249, Pierre Fenaux, Norbert Gattermann, John F. Seymour, Eva Hellström-Lindberg, Ghulam J. Mufti, Ulrich Duehrsen, Steven D. Gore, Fernando Ramos, Odile Beyne-Rauzy, Alan List, David McKenzie, Jay Backstrom and Charles L. Beach

    Version of Record online : 5 FEB 2010, DOI: 10.1111/j.1365-2141.2010.08082.x

  9. Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group

    British Journal of Haematology

    Volume 172, Issue 6, March 2016, Pages: 930–936, Annamaria M. Cseh, Charlotte M. Niemeyer, Ayami Yoshimi, Albert Catala, Michael C. Frühwald, Henrik Hasle, Mary M. van den Heuvel-Eibrink, Melchior Lauten, Barbara De Moerloose, Owen P. Smith, Toralf Bernig, Bernd Gruhn, Andreas E. Kulozik, Markus Metzler, Lale Olcay, Meinolf Suttorp, Ingrid Furlan, Brigitte Strahm and Christian Flotho

    Version of Record online : 13 JAN 2016, DOI: 10.1111/bjh.13915

  10. You have free access to this content
    Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes

    Cancer

    Volume 117, Issue 12, 15 June 2011, Pages: 2697–2702, Lewis R. Silverman, Pierre Fenaux, Ghulam J. Mufti, Valeria Santini, Eva Hellström-Lindberg, Norbert Gattermann, Guillermo Sanz, Alan F. List, Steven D. Gore and John F. Seymour

    Version of Record online : 10 JAN 2011, DOI: 10.1002/cncr.25774

  11. Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies

    The Journal of Clinical Pharmacology

    Volume 54, Issue 6, June 2014, Pages: 630–639, Eric Laille, Michael R. Savona, Bart L. Scott, Thomas E. Boyd, Qian Dong and Barry Skikne

    Version of Record online : 18 JAN 2014, DOI: 10.1002/jcph.251

  12. A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 34, Issue 5, May 2014, Pages: 440–451, Eric Laille, Sanjay Goel, Alain C. Mita, Nashat Y. Gabrail, Kevin Kelly, Liangang Liu, Stephen Songer and Charles L. Beach

    Version of Record online : 8 NOV 2013, DOI: 10.1002/phar.1371

  13. You have full text access to this OnlineOpen article
    Lack of cross-resistance to FF-10501, an inhibitor of inosine-5′-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines

    Pharmacology Research & Perspectives

    Volume 4, Issue 1, February 2016, Motohiko Murase, Hiroyuki Iwamura, Kensuke Komatsu, Motoki Saito, Toshihiko Maekawa, Takaaki Nakamura, Takuya Yokokawa and Yasuhiro Shimada

    Version of Record online : 28 JAN 2016, DOI: 10.1002/prp2.206

  14. Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes

    The Journal of Clinical Pharmacology

    Volume 45, Issue 5, May 2005, Pages: 597–602, Dr Guido Marcucci, Dr Lewis Silverman, Dr Mark Eller, Ms Linda Lintz and Dr C. L. Beach

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270004271947

  15. You have full text access to this OnlineOpen article
    Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia

    Cancer Medicine

    Volume 3, Issue 6, December 2014, Pages: 1570–1578, Santhosh K. Sadashiv, Christie Hilton, Cyrus Khan, James M. Rossetti, Heather L. Benjamin, Salman Fazal, Entezam Sahovic, Richard K. Shadduck and John Lister

    Version of Record online : 15 AUG 2014, DOI: 10.1002/cam4.321

  16. You have free access to this content
    Activity of azacitidine in chronic myelomonocytic leukemia

    Cancer

    Volume 117, Issue 12, 15 June 2011, Pages: 2690–2696, Rubens Costa, Haifaa Abdulhaq, Bushra Haq, Richard K. Shadduck, Joan Latsko, Mazen Zenati, Folefac D. Atem, James M. Rossetti, Entezam A. Sahovic and John Lister

    Version of Record online : 23 DEC 2010, DOI: 10.1002/cncr.25759

  17. You have free access to this content
    Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

    British Journal of Haematology

    Volume 167, Issue 1, October 2014, Pages: 62–68, Amer M. Zeidan, Ju-Whei Lee, Thomas Prebet, Peter Greenberg, Zhuoxin Sun, Mark Juckett, Mitchell R. Smith, Elisabeth Paietta, Janice Gabrilove, Harry P. Erba, Rhett P. Katterling, Martin S. Tallman and Steven D. Gore, on behalf of the Eastern Cooperative Oncology Group (ECOG) and North American Leukemia intergroup

    Version of Record online : 4 JUL 2014, DOI: 10.1111/bjh.13008

  18. You have free access to this content
    Azacitidine for the treatment of lower risk myelodysplastic syndromes

    Cancer

    Volume 116, Issue 6, 15 March 2010, Pages: 1485–1494, Pellegrino Musto, Luca Maurillo, Alessandra Spagnoli, Antonella Gozzini, Flavia Rivellini, Monia Lunghi, Oreste Villani, Maria Antonietta Aloe-Spiriti, Adriano Venditti and Valeria Santini

    Version of Record online : 11 FEB 2010, DOI: 10.1002/cncr.24894

  19. Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy

    Asia-Pacific Journal of Clinical Oncology

    Volume 11, Issue 1, March 2015, Pages: 54–61, Zhentang Lao, Richard Yiu, Gee Chuan Wong and Aloysius Ho

    Version of Record online : 28 DEC 2014, DOI: 10.1111/ajco.12331

  20. You have free access to this content
    Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition

    British Journal of Haematology

    Volume 138, Issue 5, September 2007, Pages: 616–623, Si Ho Choi, Hyang-Min Byun, Jennifer M. Kwan, Jean-Pierre J. Issa and Allen S. Yang

    Version of Record online : 2 AUG 2007, DOI: 10.1111/j.1365-2141.2007.06707.x